Jan. 10 Company Quick Takes: Nektar gains on expanded BMS deal; plus Nurix-Sanofi, Amunix-Roche, Sorrento, Alderaan, Keytruda, Akari, Moderna

BMS, Nektar adding more combo trials to bempeg/Opdivo deal
Bristol-Myers Squibb Co. (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) will start two new registrational trials under an expanded partnership in which they are developing Nektar's bempegaldesleukin (NKTR-214) in combination with BMS's PD-1 inhibitor Opdivo nivolumab. The partners will conduct pivotal studies of the doublet to treat adjuvant melanoma

Read the full 559 word article

User Sign In